Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
2
22%
Ph not_applicable
4
44%
Ph phase_2
1
11%
Ph phase_4
1
11%

Phase Distribution

2

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 4Post-market surveillance
1(12.5%)
N/ANon-phased studies
4(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(5)
Terminated(3)
Other(1)

Detailed Status

Completed5
Withdrawn2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (25.0%)
Phase 21 (12.5%)
Phase 41 (12.5%)
N/A4 (50.0%)

Trials by Status

withdrawn222%
completed556%
terminated111%
unknown111%

Recent Activity

0 active trials
Showing 5 of 9
unknownnot_applicable

The GALAXY-1 Project

NCT05986500
completednot_applicable

sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis

NCT02702765
completednot_applicable

Direct Peritoneal Resuscitation Effects in the Damage Control Patient

NCT01771055
completed

Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C

NCT02528461
completednot_applicable

Effect of Galactose Ingestion on Postprandial Lipemia

NCT03439878
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05986500Not Applicable

The GALAXY-1 Project

Unknown
NCT02702765Not Applicable

sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis

Completed
NCT01771055Not Applicable

Direct Peritoneal Resuscitation Effects in the Damage Control Patient

Completed
NCT02528461

Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C

Completed
NCT03439878Not Applicable

Effect of Galactose Ingestion on Postprandial Lipemia

Completed
NCT01882218Phase 4

Direct Peritoneal Resuscitation Plus Conventional Resuscitation

Withdrawn
NCT00814255Phase 2

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

Completed
NCT00816478Phase 1

Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor

Terminated
NCT00816504Phase 1

Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5

Withdrawn

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9